Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Levosimendan - AbbVie/Tenax Therapeutics

Next Previous
Drug Profile

Levosimendan - AbbVie/Tenax Therapeutics

Alternative Names: Daxim; ODM 109; OR-1259; Simdax; TNX-101; TNX-102 - Tenax Therapeutics; TNX-103; TNX102

Latest Information Update: 28 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Orion
  • Developer Abbott Laboratories; AbbVie; Imperial College of Science, Technology and Medicine; Orion; Tenax Therapeutics; Yooyoung Pharmaceutical
  • Class Antiarrhythmics; Cardiotonics; Cardiovascular therapies; Hydrazones; Nitriles; Pyridazines; Small molecules; Vasodilators
  • Mechanism of Action Calcium-binding protein modulators; Calcium-sensitising phosphodiesterase inhibitors; Potassium channel agonists; Type 3 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute heart failure
  • Phase III Amyotrophic lateral sclerosis; Chronic heart failure; Low cardiac output; Pulmonary hypertension
  • Discontinued Myocardial infarction; Septic shock; Stroke; Transient ischaemic attacks

Most Recent Events

  • 20 Feb 2024 Oral levosimendan licensed to Tenax Therapeutics through expanded license agreement with Orion Corporation for Pulmonary hypertension associated with heart failure and preserved ejection fraction Worldwide
  • 07 Feb 2024 USPTO grants Notice of Allowance for use of levosimendan in Pulmonary hypertension with heart failure with preserved ejection fraction in USA
  • 10 Jan 2024 Phase-III clinical trials in Pulmonary hypertension (PH-HFpEF) in USA (IV) (NCT05983250)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top